Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Compact OEM Pressure Transducer Offers Long Term Stability

August 18, 2010 8:20 am | Product Releases | Comments

The 300 Series compact-sized pressure transducer delivers long term stability during operation. The transducer is excellent for use in dynamic or static measurement.

Achromatic Lens Are Computer-Optimized

August 18, 2010 8:15 am | Product Releases | Comments

Edmund Optics (EO), a provider of optical components, expands its selection of TECHSPEC MgF2 coated achromatic lenses. Consisting of two optical components cemented together to form an achromatic doublet...

The Big Three: Tests Manufacturers Need to Know

August 18, 2010 7:02 am | by Thor Rollins | Nelson Laboratories, Inc. | Articles | Comments

Product testing is a critical component in the development of a medical device. But how many engineers truly understand the importance of what are arguably the three most crucial tests for a medical device? This article reviews these three tests–cytotoxicity, sensitization, and irritation–and offers some insight that will ideally make them go more smoothly for engineers.

Advertisement

UTS Slotless Direct Drive Frameless Motors Offer Thin Radial Length

August 18, 2010 6:56 am | Product Releases | Comments

Applimotion’s UTS Series direct drive slotless motors now cover 29 to 240 mm diameters with thin radial length, prefect for direct drive positioning or high speed spindle applications.

How Are You Influencing Wireless Medical Technology?

August 18, 2010 6:23 am | Freescale Semiconductor, Inc. | Articles | Comments

How Are You Influencing Wireless Medical Technology?

The Critical Questions When Micromolding for an MIS Device

August 18, 2010 5:25 am | by John Whynott | Mikrotech | Articles | Comments

Asking the right questions when selecting a high performance plastic for micromolding an MIS device could reap some great competitive advantages. This article will review the micromolding process and cover the important aspects of each question that should be addressed by the outsourcing partner, the OEM, or both.

Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in...

August 18, 2010 4:36 am | by Bio-Medicine.Org | News | Comments

FREMONT, Calif., Aug. 18 /- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor...

TOPICS:

Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting

August 18, 2010 4:36 am | by Bio-Medicine.Org | News | Comments

KIRKLAND, Wash., Aug. 18 /- Cardiac Dimensions, an early stage company focused on the development of minimally invasive devices for the treatment of mitral valve disease and congestive heart failure, announced today that the 12-month follow-up results from the TITAN™ trial of the...

TOPICS:
Advertisement

Research could change course of treatment for cancer that spreads to bones

August 18, 2010 4:35 am | by EurekAlert | News | Comments

(Southern Methodist University) New research holds promise for people whose cancer has spread to their bones. A common treatment for such patients is radiosurgery ? even though little is known about its impact on bone strength, says Edmond Richer at Southern Methodist University, Dallas....

TOPICS:

Out-of-the-ordinary life science ideas offer potential business success

August 17, 2010 10:32 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

Turning a “cool idea” into the “next big thing” takes perserverence, an unwavering commitment to a vision, and usually, in the life sciences, a boatload of cash. Local entrepreneurs say the challenge lies in convincing funders (or customers) of the value proposition of the product.

TOPICS:

Think of the global good

August 17, 2010 10:31 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

In this issue we set out to address a core question: How do different types of life sciences companies make money? Yet, there's another question that we also felt it was important to address: Can a company work for the public good even when there is little or no hope of turning a profit?

TOPICS:

VCs discuss potential life science investment pitfalls

August 17, 2010 9:33 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

Two Boston VCs known for not being shy of risk, SV Life Sciences' James Garvey and PureTech Ventures' Daphne Zohar, told Mass High Tech where they're applying a higher level of scrutiny before investing and what life science categories they're avoiding like the plague.

TOPICS:

Regenerative medicine gets on a profitable roll

August 17, 2010 9:32 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

After getting off to a false start in the 1990s, the field of regenerative medicine has been reborn over the past decade. Now, several New England companies are showing that regenerative medicine - generally defined as therapy that uses living cells to repair the body - is more than just...

TOPICS:

Cardica signs contract deal with Intuitive

August 17, 2010 2:45 pm | by The Associated Press | News | Comments

Surgical systems maker Cardica Inc. said Tuesday it entered a licensing deal worth $12 million upfront with Intuitive Surgical Inc.Under the deal, Intuitive will get a worldwide, exclusive license to Cardica's intellectual property, which relates to tissue cutting, stapling and clip appliers,...

TOPICS:

Cardica 4Q loss narrows on smaller sales force

August 17, 2010 2:45 pm | by The Associated Press | News | Comments

Surgical systems maker Cardica Inc. said Tuesday its fiscal fourth quarter loss narrowed on lower costs following cuts to its sales force.The company lost $3.1 million, or 13 cents per share, compared with a loss of $3.5 million, or 22 cents per share, during the same period a year prior....

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading